Enlivex Therapeutics Ltd.
ENLV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $24 | $50 | $72 | $112 |
| - Cash | $3 | $1 | $48 | $11 |
| + Debt | $1 | $1 | $5 | $1 |
| Enterprise Value | $21 | $50 | $30 | $101 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | -$14 | -$28 | -$25 | -$19 |
| % Margin | – | – | – | – |
| Net Income | -$15 | -$29 | -$31 | -$14 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -1.56 | -2.31 | -0.54 |
| % Growth | 53.2% | 32.5% | -327.8% | – |
| Operating Cash Flow | -$13 | -$24 | -$24 | -$18 |
| Capital Expenditures | -$0 | -$0 | -$8 | -$2 |
| Free Cash Flow | -$13 | -$24 | -$32 | -$19 |